Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Q702 · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Dose escalation of Q702 in combination with fixed dose of pembrolizumab | EXPERIMENTAL | Give one week on/one week off at selected dose level |
| Dose expansion of Q702 in combination with fixed dose of pembrolizumab | EXPERIMENTAL | Give intravenously once every three week at 200 mg |
| Name | Type | Description |
|---|---|---|
| Q702 | DRUG | The study drug Q702 will be administered once daily by mouth on Days 1 through 7, Days 15 through 21 and Days 29 through 35 of every treatment cycle. |
| Pembrolizumab | BIOLOGICAL | Pembrolizumab will be administered using IV infusion on Day 1 of each 3-week treatment cycle |
Inclusion Criteria: * The participant (or legally acceptable representative if applicable) provides written informed consent for the trial. * Subjects with histologically or cytologically confirmed advanced or metastatic esophageal, gastric/GEJ, hepatocellular and cervical cancers who have progress...
Top 20 of 37 competitors
Q702 is an investigational oral small molecule being studied for the treatment of esophageal cancer. It is currently in Phase 1 clinical development as a monotherapy or in combination with pembrolizumab for patients with selected advanced solid tumors, including esophageal cancer.
Q702 is a selective tyrosine kinase inhibitor that targets Axl, Mer, and CSF1R. These are receptor tyrosine kinases involved in tumor growth and immune evasion. By inhibiting these targets, Q702 aims to modulate the tumor microenvironment and enhance anti-tumor immune responses.
Q702 is being developed by Merck & Company, Inc., a global biopharmaceutical company. Merck is conducting clinical trials to evaluate the safety and efficacy of Q702 in patients with advanced solid tumors.
Q702 is currently in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is active but not recruiting participants.
Q702 is being evaluated in a Phase 1 clinical trial with the identifier NCT05438420. This trial is studying Q702 in combination with pembrolizumab in patients with selected advanced solid tumors, including esophageal, gastric, hepatocellular, and cervical cancers. The trial is enrolling 120 participants in the United States and South Korea.
Q702 is a unique investigational compound and is not known to have alternative names. It is being studied under its development code Q702 and has not been assigned a brand name.